- Home
- GPRK vs FDMT Comparison
GPRK vs FDMT Comparison
Compare GPRK & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GPRK | FDMT |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | Colombia | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.8M | 466.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GPRK | FDMT |
|---|---|---|
| Price | $8.21 | $9.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $8.50 | ★ $34.13 |
| AVG Volume (30 Days) | ★ 821.2K | 750.3K |
| Earning Date | 02-25-2026 | 02-27-2026 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $525,938,000.00 | $120,000.00 |
| Revenue This Year | N/A | $21,227.03 |
| Revenue Next Year | N/A | $161.87 |
| P/E Ratio | $13.23 | ★ N/A |
| Revenue Growth | N/A | ★ 605.88 |
| 52 Week Low | $5.66 | $2.24 |
| 52 Week High | $9.54 | $12.34 |
Technical Indicators
Market Signals| Indicator | GPRK | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 55.46 | 58.91 |
| Support Level | $7.80 | $8.75 |
| Resistance Level | $8.68 | $9.39 |
| Average True Range (ATR) | 0.34 | 0.64 |
| MACD | 0.00 | 0.12 |
| Stochastic Oscillator | 38.76 | 82.88 |
Price Performance
Historical ComparisonAbout GPRK Geopark Ltd
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil, and Argentina. The company generates revenue from the sale of crude oil, condensate, and natural gas, net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.